Celgene (CELG ) Tops Q2 EPS by 4c, Raises FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Celgene Reports Second Quarter 2015 Operating and Financial Results
July 23, 2015 7:30 AM EDTREVLIMID® Net Product Sales $1,444 Million; Increased 19% Y/Y POMALYST®/IMNOVID® Net Product Sales $235 Million; Increased 46% Y/Y ABRAXANE® Net Product Sales $244 Million; Increased 13% Y/Y OTEZLA® Net Product Sales $90 Million
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) reported net product sales of $2,254 million for the second quarter of 2015, a 22 percent increase from the same period in 2014. The negative net impact of currency... More
